Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Ingenuity Systems has extended and expanded its existing license agreement with GlaxoSmithKline for access to Ingenuity Pathways Analysis software.
Subscribe to our email newsletter
The new agreement enables GlaxoSmithKline (GSK) to provide enterprise-wide Ingenuity Pathways Analysis (IPA) access to researchers for rapid assessment of the signaling and metabolic pathways, molecular networks, and biological processes that are most significant to disease targets. In addition, GSK will also use Ingenuity’s content and proprietary algorithms.
Jake Leschly, CEO of Ingenuity Systems, said: We are very pleased that GSK will now be able to leverage IPA and other Ingenuity information solutions at the enterprise level. Research teams across the organization will now be able to use these insights to make effective decisions as to which drug targets and compounds to pursue.